Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease

Completed · Phase 2

Conditions studied: Lymphoma

In brief

This is a clinical research study of interferon (IFN) plus chemotherapy with the standard combination of Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD). The treatment will be given to patients with Hodgkin's disease. The study will look at whether adding IFN to ABVD improves the immune response against Hodgkin's disease, and will determine whether the toxicity of ABVD is increased by adding IFN.

Key facts

Study ID

NCT01404936

Run by

M.D. Anderson Cancer Center

People needed

35

Starts

1996-07-01

Expected to finish

2011-12-01

Last updated by the study team

2013-02-01

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Hodgkin's disease patients who relapse after radiation therapy alone, or in combination with Novantrone, Oncovin, Velban, and Prednisone (NOVP); and previously untreated patients with stage III and IV who are eligible for standard ABVD therapy.
• Must have adequate bone marrow reserve Absolute neutrophil count (ANC) > 1,000/uL, Platelets > 100,000
• Left ventricular ejection fraction (LVEF) >/= 50%, serum creatinine < 2mg/dl, serum bilirubin < 2mg/dl

You may not qualify if…

• No prior therapy with Mustargen Oncovin Procarbazine Prednisone (MOPP).
• No severe pulmonary disease including Chronic obstructive pulmonary disease (COPD) and asthma.

Where it is running

• UT MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.